Waldemar Debinski - Hummelstown PA Raj K. Puri - North Potomac MD
Assignee:
Penn State University
International Classification:
A61K 39395
US Classification:
4241431, 424 852, 435 723, 530350, 514 2
Abstract:
The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule in the presence of an interleukin-4 receptor (IL-4R) blocker.
Il-13 Receptor Specific Chimeric Proteins And Uses Thereof
Raj K. Puri - North Potomac MD Waldemar Debinski - Hummelstown PA Ira Pastan - Potomac MD Nicholas Obiri - N. Potomac MD
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 1574
US Classification:
4353201, 435 697, 435328, 435334, 530351
Abstract:
The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor. The method involves providing a chimeric molecule that comprises an effector molecule attached to a circularly permuted IL-13 (âcpIL-13â) that specifically binds an IL-13 receptor and contacting the tumor cell with the chimeric molecule. The compositions include chimeric molecules comprising effector molecules such as modified Pseudomonas exotoxin attached to a cpIL-13. The invention further provides vectors encoding the chimeric molecules.
This invention provides mutant human interleukin 13 molecules showing varying specificity for the restricted (IL4 independent) IL13 receptor. The mutant hIL13 molecules include those made by substituting the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Some of the mutants retain the ability to bind and cause signaling through IL13 receptors, while other mutants do not.
This invention provides mutant hIL13 molecules include those made by substituting one or more of the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Multiply mutated forms of hIL13 conjugated to cytotoxins are used to preferentially target diseased cells over non-diseased cells.
Method For Identifying A Test Compound That Modulates Expression Of A Fra-1 Gene In A Brain Cancer Cell
Waldemar Debinski - Hershey PA, US Denise M. Gibo - Hershey PA, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
C12Q001/68 C12Q001/02 G01N033/53
US Classification:
435 6, 435 71, 435 29
Abstract:
Fra-1 serves as a target for diagnosing and treating glioblastoma multiforme and related brain cancers. Cancer in a brain tissue sample is detected by analyzing expression of Fra-1 in the sample. Brain cancer is treated by modulating Fra-1 gene expression in cells of the cancer, and by inhibiting angiogenesis associated with the cancer by interfering with Fra-1 binding to a VEGF-D promoter.
Waldemar Debinski - Hershey PA, US Jeffrey P. Thompson - Landisville PA, US
Assignee:
The Penn State Research Foundation - PA
International Classification:
C12P021/04 C12P021/06 C07K017/00 C07K014/00
US Classification:
435 6952, 435 691, 530351, 530350
Abstract:
This invention provides nucleic acid molecules encoding mutant human interleukin 13 molecules showing varying specificity for the restricted (IL4 independent) IL13 receptor. The mutant hIL13 molecules include those made by substituting the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Some of the mutants retain the ability to bind and cause signaling through IL13 receptors, while other mutants do not.
Waldemar Debinski - Hershey PA, US Neil Christensen - Harrisburg PA, US Akiva Mintz - Brooklyn NY, US
Assignee:
The Penn State Research Foundation - University Park PA
International Classification:
A01N 37/18
US Classification:
514 2
Abstract:
A method for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes the steps of formulating the anti-cancer vaccine outside of the subject and administering the vaccine to the subject in an amount sufficient to stimulate an immune response against IL-13Rα2 in the subject. A composition for stimulating a immune response against IL-13Rα2 in a subject having or at risk for developing a disease having cells expressing IL-13Rα2 includes an isolated agent that can stimulate immune response against IL-13α2.
This invention provides nucleic acid molecules encoding mutant human interleukin 13 molecules showing varying specificity for the restricted (IL4 independent) IL13 receptor. The mutant hIL13 molecules include those made by substituting the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Some of the mutants retain the ability to bind and cause signaling through IL13 receptors, while other mutants do not.
Name / Title
Company / Classification
Phones & Addresses
Waldemar Debinski Director
Salzburg Therapeutics, Inc Commercial Physical Research